Table 3.

Correlation between germline mutation status and somatic mutations.

	Univariate analysis		Multivariate analysis
	OR (95%CI)	p value	OR (95%CI)	p value
	KRAS mutation
Age of diagnosis		0.162
Gender (Female vs. Male)	0.228(0.141–0.368)	<0.001	0.229 (0.142–0.369)	<0.001
Histology (LUSC vs. LUAD)		0.258
Germline mutation (pos vs. neg)	2.156(1.202–3.866)	0.01	2.127 (1.170–3.866)	0.013
	TP53 mutation
Age of diagnosis		0.360
Gender (Female vs. Male)	0.626(0.509–0.769)	<0.001	0.678 (0.536–0.856)	0.001
Histology (LUSC vs. LUAD)	2.153(1.477–3.138)	<0.001	1.895 (1.287–2.790)	0.001
Germline mutation (pos vs. neg)	0.561(0.367–0.857)	0.008	0.577 (0.363–0.916)	0.020
	c-MET 14 skipping
Age of diagnosis	1.071(1.017–1.127)	0.009	1.076 (1.020–1.134)	0.007
Gender (Female vs. Male)		0.854
Histology (LUSC vs. LUAD)		0.581
Germline mutation (pos vs. neg)	5.888(1.838–18.867)	0.003	5.536 (1.466–20.897)	0.012
	EGFR mutation
Age of diagnosis	0.982(0.974–0.991)	<0.001	0.989 (0.978–0.999)	0.038
Gender (Female vs. Male)	3.651(2.949–4.520)	<0.001	2.925 (2.289–3.737)	<0.001
Histology (LUSC vs. LUAD)	0.110(0.066–0.182)	<0.001	0.161 (0.096–0.271)	<0.001
Germline mutation (pos vs. neg)		0.58		0.967

Odds ratios, two-sided p value and 95% confidence intervals were calculated using logistic regression models. Factors with p value < 0.1 in univariate analysis were included for multivariate logistic regression models. Gene mutation counts of TP53, KRAS, and EGFR included SNV/indel, CNV and SV.

CI confidence interval, OR Odds ratio, LUSC lung squamous carcinoma, LUAD lung adenocarcinoma.